{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:22:25Z","timestamp":1784074945839,"version":"3.55.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Takeda Development Center Americas, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>TAK-063 is an inhibitor of phosphodiesterase 10A (PDE10A), an enzyme highly expressed in medium spiny neurons of the striatum. PDE10A hydrolyzes both cyclic adenosine monophosphate and cyclic guanosine monophosphate and modulates dopamine signaling downstream of receptor activation in both direct and indirect pathways of the striatum. TAK-063 exhibited antipsychotic-like effects in animal models; however, the translatability of these models to the clinical manifestations of schizophrenia and the meaningfulness for new targets such as PDE10A has not been established.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The TAK-063 phase 1 program included a comprehensive translational development strategy with the main objective of determining whether the antipsychotic-like pharmacodynamic effects seen in nonclinical models would translate to human subjects. To evaluate this objective, we conducted a single-rising dose study (84 healthy subjects), a positron emission tomography (PET) study (12 healthy subjects), a functional magnetic resonance imaging blood oxygen level-dependent (BOLD) study (27 healthy subjects), and a multiple-rising dose study that included people with schizophrenia (30 healthy Japanese subjects and 47 subjects with stable schizophrenia). In addition, assessments of cognition and electroencephalography (27 healthy subjects and 47 subjects with stable schizophrenia) were included.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>PDE10A engagement by TAK-063 was verified with a novel PET radiotracer for use in primates and humans. TAK-063 showed favorable pharmacokinetic and safety profiles in humans, and TAK-063 reduced ketamine-induced changes in electroencephalography and BOLD signaling in animal models and healthy human subjects. In addition, analogous effects on cognition were observed in animal models and human subjects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Overall, the phase 1 results showed some consistent evidence of antipsychotic activity. This translational strategy may be valuable for the future development of novel therapeutic approaches, even when relevant nonclinical models are not available.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ijnp\/pyaa042","type":"journal-article","created":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T11:10:18Z","timestamp":1591269018000},"page":"524-532","source":"Crossref","is-referenced-by-count":7,"title":["Translational Development Strategies for TAK-063, a Phosphodiesterase 10A Inhibitor"],"prefix":"10.1093","volume":"23","author":[{"given":"Thomas A","family":"Macek","sequence":"first","affiliation":[{"name":"Takeda Development Center Americas, Inc., Deerfield, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Company Limited, Fujisawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Asin","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc., Deerfield, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhide","family":"Kimura","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Company Limited, Fujisawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,6,29]]},"reference":[{"key":"2020112601565652000_CIT0001","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/s-2007-979354","article-title":"The NMDA antagonist model for schizophrenia: promise and pitfalls","volume":"31","author":"Abi-Saab","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"2020112601565652000_CIT0002","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1124\/jpet.110.173880","article-title":"Awake rat pharmacological magnetic resonance imaging as a translational pharmacodynamic biomarker: metabotropic glutamate 2\/3 agonist modulation of ketamine-induced blood oxygenation level dependence signals","volume":"336","author":"Chin","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"2020112601565652000_CIT0003","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4088\/JCP.13049su1c.04","article-title":"Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains","volume":"75","author":"Citrome","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"2020112601565652000_CIT0004","first-page":"10","article-title":"Pharmacokinetic studies of antipsychotics in healthy volunteers versus patients","volume":"62","author":"Cutler","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"2020112601565652000_CIT0005","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1001\/archgenpsychiatry.2007.37","article-title":"Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study","volume":"65","author":"Deakin","year":"2008","journal-title":"Arch Gen Psychiatry"},{"key":"2020112601565652000_CIT0006","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/mp.2012.194","article-title":"Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans","volume":"18","author":"Driesen","year":"2013","journal-title":"Mol Psychiatry"},{"key":"2020112601565652000_CIT0007","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/0269881113512909","article-title":"Reviewing the ketamine model for schizophrenia","volume":"28","author":"Frohlich","year":"2014","journal-title":"J Psychopharmacol"},{"key":"2020112601565652000_CIT0008","doi-asserted-by":"crossref","first-page":"18438","DOI":"10.1074\/jbc.274.26.18438","article-title":"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A)","volume":"274","author":"Fujishige","year":"1999","journal-title":"J Biol Chem"},{"key":"2020112601565652000_CIT0009","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF03033576","article-title":"Developing translational animal models for symptoms of schizophrenia or bipolar mania","volume":"14","author":"Geyer","year":"2008","journal-title":"Neurotox Res"},{"key":"2020112601565652000_CIT0010","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-3-642-25761-2_2","article-title":"Role of dopamine D(2) receptors for antipsychotic activity","volume":"212","author":"Ginovart","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"2020112601565652000_CIT0011","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s40268-017-0214-8","article-title":"A randomized multiple dose pharmacokinetic study of a novel PDE10A inhibitor TAK-063 in subjects with stable schizophrenia and Japanese subjects and modeling of exposure relationships to adverse events","volume":"17","author":"Goldsmith","year":"2017","journal-title":"Drugs R D"},{"key":"2020112601565652000_CIT0012","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S0006-3223(00)01027-1","article-title":"Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications","volume":"49","author":"Green","year":"2001","journal-title":"Biol Psychiatry"},{"key":"2020112601565652000_CIT0013","doi-asserted-by":"crossref","first-page":"e0122197","DOI":"10.1371\/journal.pone.0122197","article-title":"Characterization of binding and inhibitory properties of TAK-063, a novel phosphodiesterase 10A inhibitor","volume":"10","author":"Harada","year":"2015","journal-title":"PLOS One"},{"key":"2020112601565652000_CIT0014","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.nucmedbio.2014.09.005","article-title":"Characterization of the binding properties of T-773 as a PET radioligand for phosphodiesterase 10A","volume":"42","author":"Harada","year":"2015","journal-title":"Nucl Med Biol"},{"key":"2020112601565652000_CIT0015","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1177\/0269881113495117","article-title":"A systematic review of the effects of NMDA receptor antagonists on oscillatory activity recorded in vivo","volume":"27","author":"Hunt","year":"2013","journal-title":"J Psychopharmacol"},{"key":"2020112601565652000_CIT0016","doi-asserted-by":"crossref","first-page":"9627","DOI":"10.1021\/jm5013648","article-title":"Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor","volume":"57","author":"Kunitomo","year":"2014","journal-title":"J Med Chem"},{"key":"2020112601565652000_CIT0017","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0893-133X(01)00243-3","article-title":"Effects of ketamine in normal and schizophrenic volunteers","volume":"25","author":"Lahti","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"2020112601565652000_CIT0018","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/nyas.12730","article-title":"Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia","volume":"1344","author":"Light","year":"2015","journal-title":"Ann NY Acad Sci"},{"key":"2020112601565652000_CIT0019","article-title":"TAK-063 increases gamma synchrony in subjects with schizophrenia [","author":"Macek","year":"2016"},{"key":"2020112601565652000_CIT0020","article-title":"Drug development strategies for schizophrenia using a novel PDE10A inhibitor: TAK-063","author":"Macek","year":"2016"},{"key":"2020112601565652000_CIT0021","article-title":"The effects of TAK-063 on cognition in a multiple dose, phase 1 study in healthy Japanese volunteers and subjects with schizophrenia are consistent with its somnolent effects","author":"Macek","year":"2016"},{"key":"2020112601565652000_CIT0022","doi-asserted-by":"crossref","first-page":"S218","DOI":"10.1093\/schbul\/sbx022.019","article-title":"M20. A phase 2, randomized, double-blind, placebo-controlled, parallel-group, 6-week study to evaluate the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia","author":"Macek","year":"2017","journal-title":"Schizophrenia Bull"},{"key":"2020112601565652000_CIT0023","volume-title":"Translational development strategies utilized in the development of an inhibitor of PDE10A (TAK-063)","author":"Macek","year":"2017"},{"key":"2020112601565652000_CIT0024","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1038\/npp.2010.150","article-title":"Gamma oscillatory power is impaired during cognitive control independent of medication status in first-episode schizophrenia","volume":"35","author":"Minzenberg","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"2020112601565652000_CIT0025","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0006-8993(03)02754-9","article-title":"Immunohistochemical localization of PDE10A in the rat brain","volume":"985","author":"Seeger","year":"2003","journal-title":"Brain Res"},{"key":"2020112601565652000_CIT0026","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1124\/jpet.115.230482","article-title":"The phosphodiesterase 10A selective inhibitor TAK-063 improves cognitive functions associated with schizophrenia in rodent models","volume":"356","author":"Shiraishi","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"2020112601565652000_CIT0027","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/jlcr.3284","article-title":"Development of a series of novel carbon-11 labeled PDE10A inhibitors","volume":"58","author":"Stepanov","year":"2015","journal-title":"J Labelled Comp Radiopharm"},{"key":"2020112601565652000_CIT0028","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1124\/jpet.114.218552","article-title":"In vivo pharmacological characterization of TAK-063, a potent and selective phosphodiesterase 10A inhibitor with antipsychotic-like activity in rodents","volume":"352","author":"Suzuki","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"2020112601565652000_CIT0029","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1038\/npp.2016.20","article-title":"TAK-063, a PDE10A inhibitor with balanced activation of direct and indirect pathways, provides potent antipsychotic-like effects in multiple paradigms","volume":"41","author":"Suzuki","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"2020112601565652000_CIT0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fncel.2013.00031","article-title":"NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia","volume":"7","author":"Snyder","year":"2013","journal-title":"Front Cell Neurosci"},{"key":"2020112601565652000_CIT0031","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/syn.21821","article-title":"Evaluation of a novel PDE10A PET radioligand, [(11)C]T-773, in nonhuman primates: brain and whole body PET and brain autoradiography","volume":"69","author":"Takano","year":"2015","journal-title":"Synapse"},{"key":"2020112601565652000_CIT0039","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/syn.21896","article-title":"Brain PET measurement of PDE10A occupancy by TAK-063, a new PDE10A inhibitor, using [11C]T-773 in nonhuman primates","volume":"70","author":"Takano","year":"2016","journal-title":"Synapse"},{"key":"2020112601565652000_CIT0032","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.neuroimage.2016.06.047","article-title":"A human [(11)C]T-773 PET study of PDE10A binding after oral administration of TAK-063, a PDE10A inhibitor","volume":"141","author":"Takano","year":"2016","journal-title":"Neuroimage"},{"key":"2020112601565652000_CIT0034","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/bcpt.12964","article-title":"Pre-clinical characterization of absorption, distribution, metabolism and excretion properties of TAK-063","volume":"122","author":"Tohyama","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2020112601565652000_CIT0035","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.neuroscience.2016.10.006","article-title":"TAK-063, a phosphodiesterase 10A inhibitor, modulates neuronal activity in various brain regions in phMRI and EEG studies with and without ketamine challenge","volume":"339","author":"Tomimatsu","year":"2016","journal-title":"Neuroscience"},{"key":"2020112601565652000_CIT0036","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11307-015-0822-z","article-title":"Molecular imaging of PDE10A knockout mice with a novel PET radiotracer: [(11)C]T-773","volume":"17","author":"T\u00f3th","year":"2015","journal-title":"Mol Imaging Biol"},{"key":"2020112601565652000_CIT0037","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1007\/s00213-016-4412-9","article-title":"A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor","volume":"233","author":"Tsai","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"2020112601565652000_CIT0038","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00213-019-05366-1","article-title":"A randomized, placebo-controlled, phase 1 study to evaluate the effects of TAK-063 on ketamine-induced changes in fMRI BOLD signal in healthy subjects","volume":"237","author":"Yurgelun-Todd","year":"2020","journal-title":"Psychopharmacology"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyaa042\/33517712\/pyaa042.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/23\/8\/524\/34544746\/pyaa042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/23\/8\/524\/34544746\/pyaa042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T06:58:21Z","timestamp":1606373901000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/23\/8\/524\/5864761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,29]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,11,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyaa042","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8]]},"published":{"date-parts":[[2020,6,29]]}}}